Introduction

Endometriosis (EMs) is a chronic inflammatory disease that affects nearly 10% of females of reproductive age worldwide [1]. Multiple theories on the pathophysiology of endometriosis, including ectopic implantation, coelomic metaplasia, and immune factors, have been proposed to elucidate the pathophysiology of endometriosis [2]. Notable changes in the local immune microenvironment of endometriosis lesions have been detected, including the infiltration and differentiation of diverse immune cells types and the aggregation of chemokines and cytokines [3]. Macrophages are reported to be one of the predominant cells present in ectopic endometrial lesions, and interleukin-1β (IL-1β)’s release promotes ectopic endometrial stromal cells (eESCs) proliferation [4, 5]. IL-8-Ab reduced the volume of lesions and ameliorated fibrosis and adhesion in monkey endometriosis models [6]. The interplay between infiltrated immune cells and eESCs prompts genetic and epigenetic modifications in the eESCs. Subsequently, these eESCs changes cause molecular changes and dysfunction in immune cells.

Interleukin-33 (IL-33), a member of the IL-1β family, is secreted by macrophages. Previous studies have indicated that IL-33 has the potential to stimulate tumor cell proliferation and neovascularization in ovarian cancer [7]. Knockout of IL-33 in mouse endometriosis models has led to a significant decrease in endometriotic lesion volume [8]. It is also worth mentioning that IL-33 induces macrophage anti-inflammatory polarization and stimulates the formation of splenic red pulp macrophages (RPMs) that regulate erythrocyte homeostasis and support iron recycling [9, 10]. Our team has also discovered a significant promoting effect of macrophages on endometriosis [11]. We thus postulate that macrophage-derived IL-33 may regulate eESCs survival, which ultimately advances the progression of endometriosis. However, the the complete role of IL-33 in the development of endometriosis requires further exploration.

Ferroptosis is a newly discovered programmed cell death process characterized by iron-dependent accumulation of reactive oxygen species (ROS) and lipid peroxidation [12, 13]. The key molecule in ferroptosis, SLC7A11, is a component of the L-cystine/L-glutamic acid reverse transporter system (Xct) that mediates the transmembrane transport of glutamate and cysteine. Cysteine from the extracellular space triggers glutathione (GSH) synthesis, maintaining the GSH/GSSG redox balance. Glutathione peroxidase 4 (GPX4) also plays a critical role in ferroptosis by efficiently reducing lipid hydroperoxides that accumulate in the membrane of cells undergoing ferroptosis [14,15,16]. A study reported that the macrophages of pancreatic ductal adenocarcinoma (PDAC) patients undergo ferroptosis, which suppressed the macrophage defense response against tumor cells [

Fig. 8: Cartoon illustration of IL-33/ST2 derived from macrophages inhibiting ferroptosis of ESCs via p38/JNK/ATF3/SLC7A11 pathway.
figure 8

Macrophage-derived IL-33 inhibits the ATF3-mediated reduction in SLC7A11 transcript levels via the P38/JNK pathway, ultimately resulting in protection against ferroptosis in eESCs.